Stockscreener 앱 받기
15.19
0.85%
-0.13
시간 외 거래:
15.19
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Is Maze Therapeutics Inc. showing signs of accumulationQuarterly Portfolio Review & Verified Momentum Watchlists - Newser
Sentiment analysis tools applied to Maze Therapeutics Inc.New Guidance & Free Safe Entry Trade Signal Reports - Newser
Understanding Maze Therapeutics Inc.’s price movementOptions Play & Daily Profit Focused Stock Screening - Newser
What MACD and RSI say about Maze Therapeutics Inc.2025 Valuation Update & Real-Time Stock Movement Alerts - Newser
What indicators show strength in Maze Therapeutics Inc.July 2025 Setups & AI Enhanced Trading Signals - Newser
Statistical indicators supporting Maze Therapeutics Inc.’s strengthBreakout Watch & Weekly High Return Stock Forecasts - Newser
Using data models to predict Maze Therapeutics Inc. stock movementJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - Newser
Custom strategy builders for tracking Maze Therapeutics Inc.July 2025 Movers & Safe Capital Investment Plans - Newser
Maze Therapeutics Inc. stock volume spike explained2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - Newser
Risk vs reward if holding onto Maze Therapeutics Inc.July 2025 Opening Moves & Safe Entry Point Alerts - Newser
Multi asset correlation models including Maze Therapeutics Inc.Risk Management & Weekly Chart Analysis and Guides - Newser
Maze Therapeutics’ Claims For Unapproved Kidney Disease Drug Face Regulatory Scrutiny - insights.citeline.com
Should value investors consider Maze Therapeutics Inc.July 2025 Levels & Growth Focused Stock Reports - khodrobank.com
Is it too late to sell Maze Therapeutics Inc.Market Growth Report & Breakout Confirmation Trade Signals - Newser
Visual analytics tools that track Maze Therapeutics Inc. performanceProduct Launch & Free Reliable Trade Execution Plans - Newser
Maze Therapeutics initiated with a Buy at BTIG - TipRanks
BTIG initiates coverage on Maze Therapeutics with a Buy rating and PT of $30. - AInvest
Maze Therapeutics appoints Tahir as Chief Financial Officer - TipRanks
Maze Therapeutics appoints Misbah Tahir as chief financial officer - Investing.com
Maze Therapeutics Appoints Misbah Tahir as CFO - TipRanks
Maze Therapeutics Appoints Misbah Tahir as New CFO - AInvest
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer - GlobeNewswire
Former IGM Biosciences CFO Who Raised $1B Joins Maze Therapeutics Ahead of Major Clinical Milestones - Stock Titan
BTIG Initiates Maze Therapeutics at Buy With $30 Price Target - MarketScreener
Is Maze Therapeutics Inc. stock showing strong momentum2025 Institutional Moves & Technical Pattern Recognition Alerts - khodrobank.com
How to monitor Maze Therapeutics Inc. with trend dashboardsWeekly Trend Recap & Real-Time Buy Signal Alerts - Newser
Can Maze Therapeutics Inc. outperform in the next rallyLayoff News & Community Verified Trade Signals - khodrobank.com
Will Maze Therapeutics Inc. stock recover after earningsWeekly Investment Recap & AI Driven Stock Movement Reports - khodrobank.com
Maze Therapeutics Inc. Breakout Confirmed by Volume Metrics getLinesFromResByArray error: size == 0 - kangso.co.kr
Institutional scanner results for Maze Therapeutics Inc.2025 Top Gainers & Technical Confirmation Trade Alerts - Newser
Historical volatility pattern of Maze Therapeutics Inc. visualizedTrade Signal Summary & Real-Time Volume Triggers - Newser
Can trapped investors hope for a rebound in Maze Therapeutics Inc.2025 Earnings Impact & Daily Volume Surge Trade Alerts - Newser
Maze Therapeutics Inc. Approaches Psychological Resistance Level getLinesFromResByArray error: size == 0 - newsyoung.net
When is the best time to exit Maze Therapeutics Inc.Gold Moves & AI Forecast for Swing Trade Picks - Newser
1.14%
1.34%
자본화:
|
볼륨(24시간):